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Overline: Gene Therapy 1 
 2 
Single Sentence Summary:  3 
Incorporating TLR9-inhibitory sequences in the AAV vector genome inhibits 4 
immunogenicity and enhances transgene expression in multiple animal models. 5 
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Editor’s summary: 13 
 14 
Abstract: 15 
Nucleic acids are utilized in many therapeutic modalities, including gene therapy, but their 16 
ability to trigger host immune responses in vivo can lead to decreased safety and efficacy. 17 
In the case of adeno-associated viral (AAV) vectors, studies have shown that the genome of 18 
the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses 19 
foreign DNA. Here, we engineered AAV vectors to be intrinsically less immunogenic by 20 
incorporating short DNA oligonucleotides that antagonize TLR9 activation directly into the 21 
vector genome. The engineered vectors elicited markedly reduced innate immune and T 22 
cell responses and enhanced gene expression in clinically relevant mouse and pig models 23 
across different tissues, including liver, muscle and retina. Subretinal administration of 24 
higher-dose AAV in pigs resulted in photoreceptor pathology with microglia and T cell 25 
infiltration. These adverse findings were avoided in the contralateral eyes of the same 26 
animals that were injected with the engineered vectors. However, intravitreal injection of 27 
higher-dose AAV in macaques, a more immunogenic route of administration, showed that 28 
the engineered vector delayed but did not prevent clinical uveitis, suggesting that other 29 
immune factors in addition to TLR9 may contribute to intraocular inflammation in this 30 
model. Our results demonstrate that linking specific immunomodulatory non-coding 31 
sequences to much longer therapeutic nucleic acids can “cloak” the vector from inducing 32 
unwanted immune responses in multiple, but not all, models. This “coupled 33 
immunomodulation” strategy may widen the therapeutic window for AAV therapies as 34 
well as other DNA-based gene transfer methods.  35 
 36 
INTRODUCTION 37 
Gene therapy holds exciting promise for treating many genetic disorders, but host 38 
immune responses pose a major challenge for in vivo gene transfer (1). Whereas adeno-39 
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associated viral (AAV) vectors are known to be less immunogenic than other viral vectors such 1 
as adenoviruses, preclinical and clinical studies have demonstrated dose-dependent 2 
inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2-8). Examples 3 
include ocular AAV therapies leading to a permanent reduction in visual acuity following 4 
intraocular inflammation (9-11) and liver-directed therapies resulting in liver transaminase 5 
elevation, which coincides with decreased factor IX (FIX) transgene expression, likely due to 6 
AAV capsid-specific cytotoxic T cells destroying transduced hepatocytes (12, 13). More 7 
recently, deaths have been reported in a high dose systemic AAV gene therapy trial for children 8 
with X-linked myotubular myopathy (14), suggesting that we are still learning about AAV-9 
mediated toxicity and immune responses.  10 
Several studies have demonstrated a central role for Toll-like receptor 9 (TLR9), an 11 
immune sensor of DNA, in detecting AAV genomes and triggering innate immune and CD8+ T 12 
cell responses (15-18). TLRs are a family of innate immune sensors conserved across 13 
mammalian species that are found on endosomal or plasma membranes of immune cells (19). 14 
TLR9 normally senses DNA from pathogenic viruses and bacteria that contains unmethylated 15 
cytosine-phosphate-guanine (CpG) motifs, which also are present in AAV vector genomes. CpG 16 
binding to TLR9 promotes its dimerization and activates TLR9 signaling via the signaling 17 
adaptor MyD88, leading to induction of type I interferons and pro-inflammatory cytokines. 18 
Innate immune responses, such as interferon induction, trigger an antiviral state among cells, 19 
while inflammation recruits other immune cells to the site of infection and primes adaptive 20 
immune responses (15, 16). In addition to TLR9, TLR2 is implicated in sensing the AAV capsid 21 
(20).  22 
One strategy for blocking TLR9 activation is the administration of specific short single-23 
stranded DNA oligonucleotides (typically 12 – 24 nt) that antagonize TLR9 activation (hereby 24 
termed “TLR9i” for TLR9-inhibitory). Structural studies recently described two different TLR9i 25 
sequences that formed stem-loop structures that fit snugly into the interior of the ring structure of 26 
TLR9, preventing dimerization and activation (21). Furthermore, the binding site of TLR9i 27 
oligonucleotides on TLR9 partially overlapped with that of CpG DNA, and the TLR9i 28 
oligonucleotide tested possessed higher binding affinity for TLR9 than CpG DNA. TLR9i 29 
sequences have been tested extensively in the literature as a standalone agent co-administered 30 
with inflammatory DNA ligands, but this strategy likely requires a large amount of 31 
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oligonucleotide to inhibit all TLR9 molecules, which we speculate may be less feasible for 1 
clinical applications. Here, we hypothesized that the immune-inhibitory activity of short TLR9i 2 
sequences remained functional in a much longer strand of DNA and could be utilized to dampen 3 
immune responses to AAV vectors by directly incorporating them into the vector genome. 4 
 5 
RESULTS 6 
TLR9i sequences efficiently inhibit inflammation when applied in cis with CpG-containing 7 
oligonucleotides 8 
To test this hypothesis, we first selected multiple TLR9i sequences described in the 9 
literature and individually linked each of them directly to a 24 nt-long highly inflammatory 10 
oligodeoxyribonucleotide (ODN), ODN 2006, which contained 4 CpG sites (22), resulting in 11 
fusion constructs hereafter termed “ODN 2006-TLR9i”. Using a TLR9 reporter cell assay, we 12 
observed that treatment of cells with ODN 2006-TLR9i oligonucleotides (with the ODN 2006 13 
sequence at the 5’ end) resulted in markedly reduced NF-kB response compared to ODN 2006 14 
linked to two separate control sequences not expected to stimulate or inhibit TLR9 (control1 or 15 
control2), demonstrating that TLR9i sequences are able to function in cis (fig. S1A and see table 16 
S1 for sequences). Insertion of a 5 nt intervening sequence (AAAAA) between ODN 2006 and 17 
selected TLR9i sequences (ODN 2088 or TTAGGG) yielded similar results, suggesting TLR9i 18 
sequences also can function when they are distal to CpG motifs (fig. S1B). When the order of 19 
ODN 2006 and the covalently linked TLR9i sequence was reversed so that the TLR9i sequence 20 
was at the 5’ end, a similar reduction in NF-kB response, as well as a reduction in the pro-21 
inflammatory cytokine IL-8, were observed (fig. S1C). We identified a condition in which ODN 22 
2006-control2 (in cis) gave comparable NF-kB response as ODN 2006 and control2 co-23 
administered at the same concentration (in trans) and observed that ODN 2006-TTAGGG 24 
blocked ~80% of induced NF-kB response, while co-administration of ODN 2006 and TTAGGG 25 
only inhibited ~35% of induced NF-kB response (fig. S1D). Thus, incorporation of a TLR9i 26 
sequence within the same molecule as an inflammatory DNA sequence could be more effective 27 
at dampening inflammation than administering it as a separate molecule. ODN TTAGGG, a well-28 
known TLR9i sequence derived from mammalian telomeres (23), did not inhibit the activation of 29 
TLR7 or TLR2/6 (sensors of microbial RNA and lipoproteins, respectively) even at high 30 
concentration, supporting its specificity for TLR9 (fig. S1E and S1F). 31 




Incorporation of io1 into a self-complementary AAV8 vector reduces interferon responses 2 
and macrophage infiltration in mouse liver and boosts factor IX expression 3 
Next, we evaluated the ability of TLR9-inhibitory sequences incorporated within AAV 4 
genomes to reduce innate and adaptive immune responses to gene therapy in vivo. We used 5 
multiple clinically relevant target tissues and routes of administration in both small and large 6 
animal models: (1) liver following an intravenous injection in mice, (2) skeletal muscle 7 
following an intramuscular injection in mice, (3) retina following an intravitreal injection in 8 
mice, (4) retina following a subretinal injection in outbred pigs, and (5) retina following an 9 
intravitreal injection in outbred macaques. In addition, we tested primary human immune cells 10 
for innate immune responses in vitro.  11 
We first inserted an oligonucleotide consisting of three copies of ODN TTAGGG 12 
separated by short AAAAA linkers (see table S1 for sequence and Fig. 1A for vector 13 
organization, hereafter termed “io1” for “inflammation-inhibiting oligonucleotide 1”) into the 5’ 14 
untranslated region (UTR) of a self-complementary (sc) AAV vector plasmid encoding human 15 
factor IX (FIX) under the control of a liver-specific transthyretin promoter (16). We chose 16 
scAAV vectors for proof-of-concept as they have been shown to trigger TLR9-dependent innate 17 
immune responses in the liver of mice efficiently after intravenous (i.v.) administration (16).  18 
As expected, systemic administration of 1 x 1011 vector genomes (vg) (equivalent to ~4 x 19 
1012 vg/kg, a therapeutically relevant dose in the clinic) of scAAV8.FIX in mice stimulated 20 
moderate type I interferon (Ifnb1 and Ifna13) gene expression in the liver at 2 hours post-21 
injection (hpi), the peak time point as previously described (16). In contrast, the same dose of 22 
scAAV8.FIX.io1 elicited no detectable innate immune response in the liver (Fig. 1B). 23 
scAAV8.FIX.io1 treatment also did not elevate interferon gene expression compared to PBS 24 
treatment 4 hpi (fig. S2). Administration of 10-fold lower doses (1 x 1010 vg) of either 25 
scAAV8.FIX or scAAV8.FIX.io1 did not trigger interferon responses in the liver, consistent with 26 
the immune response being AAV-dose dependent (Fig. 1C). We confirmed with Tlr9-/- and 27 
Myd88-/- mice that the innate immune response to self-complementary AAV was indeed 28 
dependent on the TLR9/MyD88 pathway (Fig. 1D and 1E), as previously shown in the literature 29 
(15-17). Whereas scAAV8.FIX stimulated macrophage infiltration of the liver, scAAV.FIX.io1 30 
avoided immune cell infiltration (Fig. 1F).   31 
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When we studied transgene expression, we observed that scAAV8.FIX.io1 enhanced 1 
human FIX in plasma nearly 3-fold compared to scAAV8.FIX 28 days post-injection (dpi) (Fig. 2 
1G), consistent with published findings that Tlr9-/- mice expressed more FIX than wild-type mice 3 
after AAV treatment and substantiating an important role for TLR9-mediated immune responses 4 
in AAV transgene expression (16). In experimental conditions where an innate immune response 5 
was not triggered (administration of 10-fold lower doses of AAV or administration to Myd88-/- 6 
mice), scAAV8.FIX.io1 did not lead to an enhancement in FIX expression (Fig. 1H and 1I), 7 
suggesting that scAAV8.FIX and scAAV8.FIX.io1 do not have inherently different potencies. 8 
We observed the development of comparable amounts of neutralizing antibody (NAb) titers at 28 9 
dpi against AAV8 for both scAAV8.FIX and scAAV8.FIX.io1, in agreement with previous 10 
observations that Tlr9-/- and wild-type mice develop similar antibody titers by this time point 11 
(16) (fig. S3A-D). Together, these results indicated that incorporation of io1 into an scAAV 12 
vector evaded innate immune responses in the liver and enhanced transgene expression following 13 
intravenous administration. 14 
 15 
Incorporation of io2 into an AAVrh32.33 vector reduces anti-capsid T cell responses and 16 
cytotoxic T cell infiltration in mouse muscle and enhances gene transfer 17 
Whereas dose-dependent immune responses are well-appreciated in systemic AAV 18 
applications in the clinic, robust T cell responses are generally not observed in mice upon 19 
intravenous AAV administration. Similarly, in our intravenous scAAV8.FIX experiments, we 20 
did not detect appreciable CD8+ T cell responses against the AAV8 capsid in an IFN-g enzyme-21 
linked immune absorbent spot (ELISpot) assay (fig. S4). To test the effect of our strategy on 22 
anti-capsid T cell responses, we modeled a more immunogenic condition in mice by utilizing 23 
intramuscular delivery and the AAVrh32.33 capsid (hereafter referred to as rh32.33), a uniquely 24 
immunogenic capsid in mice. This combination has been shown to elicit robust CD8+ T cell 25 
responses against rh32.33 capsid and local infiltration of cytotoxic T cells into muscle in a 26 
TLR9-dependent manner (17, 24). We tested single-stranded AAV vectors, which are more 27 
widely used because of their larger coding capacity. We observed that at a dose of 1 x 1010 vg 28 
injected into the quadriceps muscle, rh32.33.GFP triggered a range of CD8+ T cell responses 29 
against an immunodominant capsid epitope at 21 dpi, with 7 of 10 animals showing positive T 30 
cell reactivity (Fig. 2A, left panel). In contrast, rh32.33.GFP.io2, which harbors inflammation-31 
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inhibiting oligonucleotide 2 (io2) designed for single-stranded vectors (see table S1 for sequence 1 
and fig. S5A for design considerations and vector organization), showed little CD8+ T cell 2 
response (1 of 10 animals positive) and was not statistically different from PBS treatment. We 3 
confirmed with Myd88-/- mice that development of CD8+ T cell responses against rh32.33 capsid 4 
depended on MyD88(15, 17) (Fig. 2A, middle panel). Cytotoxic T cell infiltrates have been 5 
observed in muscle biopsies of patients receiving intramuscular AAV gene therapy (25-27). 6 
Thus, we further characterized immune cell infiltration into the local tissue environment. We 7 
observed robust CD8+ T cell infiltration into muscle samples from rh32.33.GFP-injected 8 
animals, and approximately one-third were positive for granzyme B - a marker for activated 9 
cytotoxic T cells - while no CD8+ T cell infiltration was observed in any of the eight 10 
rh32.33.GFP.io2-injected muscle samples, suggesting that the presence of io2 prevented capsid-11 
directed CD8+ T cell responses and infiltration (Fig. 2B–D).  12 
At a higher dose of 1 x 1011 vg, both rh32.33.GFP and rh32.33.GFP.io2 elicited 13 
extremely high capsid-directed T cell responses (~800 – 1000 SFU/million splenocytes) (Fig. 14 
2A, right panel). rh32.33.GFP.io2 muscle sections exhibited higher GFP expression than those 15 
with the unmodified vector by immunohistochemical analysis, suggesting that io2 might be 16 
partially protective against T cell responses at the higher dose (Fig. 2E). To facilitate 17 
quantification of transgene expression, we tested a similar dose of a single-stranded vector 18 
expressing human FIX under the control of a ubiquitous CAG promoter (rh32.33.FIX or 19 
rh32.33.FIX.io2) intramuscularly, and likewise observed that the engineered vector augmented 20 
human FIX in vivo (Fig. 2F). Together, these results indicated that incorporation of io2 into a 21 
single-stranded AAV vector reduced CD8+ T cell responses and infiltration and enhanced 22 
transgene expression following intramuscular AAV administration.  23 
 24 
Engineered AAV2 vector diminishes inflammatory and innate immune responses in 25 
primary human plasmacytoid and monocyte-derived dendritic cells 26 
Plasmacytoid dendritic cells (pDCs) are critical for mounting a TLR9/MyD88-dependent 27 
early innate immune response to AAV vectors (15) and they subsequently orchestrate anti-capsid 28 
CD8+ T cell responses in vivo by activating conventional DCs to cross-present capsid antigen 29 
(18). To further evaluate the effect of our TLR9-inhibitory approach on human innate immune 30 
responses, we tested primary human peripheral blood mononuclear cells from thirteen healthy 31 
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donors with single-stranded AAV2 vectors (termed AAV.GFP.WPRE to distinguish it from the 1 
previous AAV.GFP vector) in vitro (28) (fig. S5B). AAV2.GFP.WPRE.io2 elicited lower IL-1b 2 
cytokine responses than the unmodified vector in pDCs from nine out of ten donors whose cells 3 
responded to AAV infection, and in monocyte-derived dendritic cells (moDCs) from nine out of 4 
eleven donors (Fig. 2G, fig. S6). Cells from only a few donors responded to AAV infection with 5 
IL-6 cytokine responses and we did not observe statistically significant differences between the 6 
two vectors (fig. S7). Furthermore, we found that AAV2.GFP.WPRE.io2 also elicited reduced 7 
IFN-b cytokine responses compared to AAV2.GFP.WPRE (Fig. 2H). These results underscored 8 
the value of our approach in evading innate immune responses in human pDCs. 9 
 10 
Engineered vector reduces ocular T cell infiltration while augmenting number of 11 
transgene-expressing retinal cells and expression of transgene per cell in mice 12 
The eye is often described as “immune-privileged” due in part to the presence of a blood-13 
retina barrier that limits the entry of immune cells and a microenvironment rich in 14 
immunosuppressive factors. However, AAV dose-dependent intraocular inflammation and a few 15 
instances of persistent loss of visual acuity have been independently reported in clinical trials 16 
following subretinal AAV administration despite prophylactic immunosuppression (9-11). In 17 
addition to safety considerations, ocular inflammation also may reduce efficacy directly by 18 
inducing pathology in retinal cells, or indirectly by mandating the use of lower, sub-optimal 19 
doses.  20 
To test if our TLR9-inhibitory strategy could be beneficial for ocular gene therapies, we 21 
started with intravitreal administration in mice, a more immunogenic route of administration in 22 
the eye compared to subretinal administration, but sparsely studied for immune responses 23 
beyond neutralizing antibody formation. Following intravitreal injection of 1 x 1010 vg of AAV2 24 
vectors (fig. S5B), in vivo retinal imaging with non-invasive optical coherence tomography 25 
(OCT) clearly detected local inflammation ~10 dpi, featuring subtle optic disc swelling, retinal 26 
vascular changes and cellular infiltration of the vitreous cavity (29) (Fig. 3A and fig. S8A). This 27 
inflammatory response is consistent with the anatomical distribution and phenotype seen in 28 
ocular clinical trials but has not been reported before in mice (5). We dissociated eye tissues for 29 
flow cytometry analysis and surprisingly observed robust CD45+ leukocyte infiltrate, comprising 30 
CD3+ T cell and CD8+ T cell populations. These results are consistent with adaptive T cell 31 
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responses in the eye. We took advantage of this model to test our strategy and found that 1 
AAV2.GFP.WPRE.io2 reduced ocular T cell numbers compared to AAV2.GFP.WPRE (Fig. 3B, 2 
fig. S8B and fig. S9).  3 
Crucially, incorporation of io2 resulted in earlier, more extensive and greater sustained 4 
expression of GFP transgene in vivo observable by longitudinal intravital retinal imaging (Fig. 5 
3C and fig. S10A). Flow cytometry analysis of dissociated retinas confirmed a multi-fold boost 6 
in the number of GFP+ retinal cells, and further revealed that GFP mean fluorescence intensity 7 
was higher on a per cell basis (Fig. 3D and fig. S10B). In addition, expression of the GFP 8 
transgene did not appear to impact the overall viability of retinal cells (fig. S10C). These 9 
observations on the magnitude and kinetics of transgene expression imply that evasion of TLR9-10 
mediated immune responses enhanced viral transduction and/or survival of transduced retinal 11 
cells. Together, our results indicated that intravitreal AAV administration stimulated ocular T 12 
cell infiltration in mice, and that incorporation of io2 diminished local T cell numbers while 13 
allowing greater transgene expression by boosting both the number of GFP+ cells and the degree 14 
of GFP expression per transduced cell. 15 
 16 
Subretinal injection of AAV8 in a pig model elicits cone photoreceptor pathology with 17 
microglia and T cell infiltration in the retina, which are evaded by engineered vector 18 
Next, we studied subretinal AAV administration, which is a more commonly used route 19 
of administration in ocular gene therapy programs. In the mouse eye, subretinal AAV has been 20 
regarded as minimally immunogenic; hence we studied immune responses and pathology in the 21 
retina using a pig model, as large animal studies recapitulate intraocular inflammation observed 22 
in clinical trials (30, 31), and pig and human eyes share similarities in size and morphology (32). 23 
We injected a single-stranded AAV8 vector, AAV8.GFP or AAV8.GFP.io2 (fig. S5A, table S2 24 
and fig. S11), and we selected an intermediate dose of 4 x 1011 vg per eye, based on published 25 
reports showing inflammation in patients at 1011 to 1012 vg per eye (9-11). To model a more 26 
immunogenic condition, systemic steroid treatment was not used.  27 
Interestingly, we observed that at 6 weeks post-injection (wpi), in all five AAV-injected 28 
outbred pigs, AAV8.GFP led to a marked loss, shortening or altered morphology of cone outer 29 
segments as labeled by expression of opsins (Fig. 4A and fig. S12A), suggesting AAV-induced 30 
pathology in cone photoreceptors, the type of photoreceptors which are critical for high-acuity 31 
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vision. In contrast, contralateral eyes injected with AAV8.GFP.io2 showed substantially better 1 
preservation of cone outer segments and appeared more morphologically similar to un-injected 2 
or vehicle-injected eyes, which was verified by quantification of the length of GFP+ cones (fig. 3 
S13A). We further confirmed these findings by performing cone arrestin staining which labels 4 
the entire cone photoreceptor (fig. S12B). In addition, we observed in two of five animals - 5 
animals 23585 and 23586 – apparent loss or retraction of cone pedicles (the synaptic terminals of 6 
cone photoreceptors important for transferring the light signal onto the dendrites of bipolar cells 7 
and horizontal cells) with AAV8.GFP; no such loss was observed in eyes injected with 8 
AAV8.GFP.io2 (see Fig. 4A and fig. S12B).  9 
In conjunction with the immunohistochemistry, we examined retinal images from in vivo 10 
OCT. The OCT imaging focused on areas of the fundus that began at the optic nerve head and 11 
ended ~ 13mm superior to the nerve head and centered between the two major ascending 12 
vascular processes. This strategy provided a broad assessment of the extent of damage to outer 13 
retinal lamination (see fig. S14 for definitions and examples). At euthanasia, the GFP+ area was 14 
located in the dissected eyecup and superimposed on the OCT fundus image (fig. S15B and 15 
S15C). In all injected eyes, there was an area of severe laminar damage surrounding the site of 16 
the subretinal injection, which was further surrounded by a region of non-severe laminar 17 
disruption (fig. S14). In the vehicle-injected retina, the laminar changes evident at 2 wpi were 18 
reduced at 6 wpi (fig. S14A and S15A). For two AAV-injected animals (23586 and 23587), 19 
GFP+ regions in both eyes were most completely visualized by OCT b-scan images (fig S15B 20 
and S15C). We analyzed these eyes as they provided the best estimates of areas of laminar 21 
changes over time. In both animals, laminar changes were similar between right (OD) and left 22 
(OS) eyes at 2 wpi (fig. S14B, S14C, S15B and S15C). At 6 wpi, both AAV8.GFP.io2-injected 23 
right eyes (OD) had reduced areas of severe laminar damage, similar to the vehicle treated eye. 24 
In contrast, the large areas of severe laminar damage were maintained in both AAV8.GFP-25 
treated left eyes (OS). In addition, animal 23585 experienced severe vitritis at 2 wpi in its 26 
AAV8.GFP-treated eye, but not the contralateral eye treated with AAV8.GFP.io2 (fig. S16 and 27 
table S3). Together, these data demonstrated that subretinal administration of higher doses of 28 
AAV triggered photoreceptor pathology and the engineered vector reduced the induction of such 29 
pathology. 30 
Confidential - Manuscript 
12 
 
 We next undertook a detailed analysis of immune responses at the cellular level in the pig 1 
retina at 6 wpi. Microglia are the resident innate immune cells of the retina and reports in the 2 
literature suggest that CNS microglia can respond to CpG ligands (33). Iba1 staining of un-3 
injected and vehicle-injected eyes showed a ramified staining pattern outside the outer nuclear 4 
layer (ONL), consistent with resting microglia (Fig. 4B). Iba1 signal increased in all AAV-5 
injected eyes (Fig. 4B), suggesting microglia activation and proliferation. Strikingly, the 6 
unmodified vector AAV8.GFP stimulated robust microglia infiltration into the ONL (extension 7 
of microglial processes into the photoreceptor layer, as well as infiltration of amoeboid-shaped 8 
cells, indicative of activated microglia) in animals 23585 and 23586, which was not observed for 9 
the engineered vector AAV8.GFP.io2 in the contralateral eyes (Fig. 4B and fig. S13B). In these 10 
same animals, we detected elevated numbers of CD8+ T cells infiltrating the outer and inner 11 
retina in the eye that received AAV8.GFP, but not in the contralateral eye receiving 12 
AAV8.GFP.io2 (Fig. 4C and fig. S13C). Interestingly, while both AAV8.GFP-treated eyes in 13 
animals 23585 and 23586 showed substantial microglia and T cell infiltration in the retina via 14 
histology, only the former presented with vitritis during clinical examinations, implying that 15 
clinically observable inflammation incompletely captures the extent of inflammation, particularly 16 
tissue-localized immune responses in the retina. Taken together (see summary in table S3), these 17 
data strongly suggest that, unlike the unmodified vector, the engineered vector carrying TLR9-18 
inhibitory sequences could avoid eliciting undesirable innate and adaptive immune cell responses 19 
in the retina. We did not observe enhanced GFP expression in photoreceptors of AAV8.GFP.io2-20 
treated eyes compared to AAV8.GFP (fig. S13C), suggesting that kinetics and impact of immune 21 
responses in the subretinal space are different than those in other tissues. It is possible that a 22 
longer in-life study may yield different results given the striking pathology and immune 23 
responses observed in AAV8.GFP eyes.  24 
 25 
Engineered vector delays, but does not prevent, intraocular inflammation following 26 
intravitreal AAV2 administration in non-human primates 27 
 Encouraged by the benefits of io2 incorporation in the intravitreal AAV2 mouse and 28 
subretinal AAV8 pig studies, we next performed a non-human primate (NHP) study testing 29 
intravitreal administration of a therapeutically relevant vector encoding aflibercept. Aflibercept 30 
is composed of the binding domains of two human vascular endothelial growth factor (VEGF) 31 
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receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1) and is approved 1 
for use to treat wet age-related macular degeneration. Five cynomolgus macaques per group were 2 
bilaterally injected with the single-stranded vector AAV2.aflibercept or AAV2.aflibercept.io2 at 3 
1 x 1011 vg or 5 x 1011 vg, with or without prophylactic systemic steroid treatment (fig. S5C, fig. 4 
S17 and Fig. 5A). Three macaques received vehicle injections and served as negative controls. 5 
Clinical intraocular inflammation in the animals was tracked weekly via ophthalmic 6 
examinations and graded according to the SUN criteria system (score of 0 – 4) over the course of 7 
the 12-week study. Clinical uveitis was defined as an aqueous cell (AC) or vitreous cell (VC) 8 
score of 3 or higher that predicated need for treatment. All animals that experienced clinical 9 
uveitis were treated with systemic steroid administration until inflammation resolved.  10 
 As expected, uveitis occurred in a dose-dependent manner (Fig. 5A; compare Group 2 to 11 
4 and Group 3 to 5), beginning 2 – 6 weeks after AAV dosing for the majority of animals that 12 
experienced inflammation. While AAV2.aflibercept.io2 did not reduce the incidence of clinical 13 
uveitis at 5 x 1011 vg (Fig. 5A; compare Group 4 to 5 and Group 6 to 7), incorporation of io2 at 14 
this dose delayed clinical uveitis by ~10 days both with and without prophylactic systemic 15 
steroids, although these differences did not reach statistical significance. Use of prophylactic 16 
systemic steroids similarly failed to reduce the incidence of clinical uveitis, but we did note a 17 
delay by ~22 days for both AAV2.aflibercept and AAV2.aflibercept.io2 (Fig. 5A, compare 18 
Group 4 to 6 and Group 5 to 7). The combination of io2 and prophylactic systemic steroids gave 19 
the latest onset of clinical uveitis at the 5 x 1011 vg dose (Fig. 5A, Group 7), suggesting that the 20 
effects of io2 and steroids were additive.  21 
 To measure transgene expression, we quantified aflibercept concentration in the vitreous 22 
humor of one eye of each animal upon euthanasia 12 weeks after AAV administration (Fig. 5B). 23 
We observed substantial variation in aflibercept concentrations among animals of each group and 24 
did not detect any statistically significant differences between groups. However, we did note that 25 
AAV2.aflibercept.io2 resulted in an approximately 2-fold enhancement in average aflibercept 26 
expression compared to AAV2.aflibercept at both the 1 x 1011 vg and 5 x 1011 vg doses (Fig. 5B, 27 
compare Group 2 to 3 and Group 4 to 5). The use of prophylactic systemic steroids did not boost 28 
aflibercept expression (Fig. 5B, compare Groups 6 and 7 to Groups 4 and 5). Comparing the 1 x 29 
1011 vg and 5 x 1011 vg groups, there was no evidence of a dose-dependent increase in aflibercept 30 
concentrations (Fig. 5B; compare Groups 2 and 3 to Groups 4 and 5), in line with a previous 31 
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intravitreal AAV study in NHPs showing that a 10-fold higher AAV dose only resulted in 2-fold 1 
more aflibercept expression (34). Together, these results suggest that the engineered vector might 2 
enhance transgene expression and delay clinical uveitis in NHP eyes. However, they also 3 
highlight that other immune factors in addition to TLR9 might contribute to intraocular 4 
inflammation in this highly immunogenic route of administration and model. 5 
 6 
DISCUSSION 7 
Our results demonstrated that the immune-inhibitory activity of short TLR9i sequences 8 
remained functional in a much longer strand of DNA, the AAV vector genome. During in vivo 9 
gene therapy, AAV can be taken up by TLR9+ immune cells such as plasmacytoid dendritic cells 10 
and the vector genome may become exposed during endosomal trafficking and detected by 11 
TLR9. We postulate that incorporation of TLR9i sequences reduces the immune response by out-12 
competing CpG motifs in the same vector genome for TLR9 binding, and consequently prevents 13 
TLR9 dimerization and activation. 14 
The TLR9-inhibitory approach described here can be easily and readily integrated into 15 
existing AAV vectors. To translate our results into the clinic, io1 or io2 could be incorporated 16 
into therapeutic vectors and characterized for safety and efficacy in preclinical studies. 17 
Furthermore, AAV vectors that have previously experienced robust immunogenicity during 18 
clinical testing may be good candidates for incorporating TLR9i sequences. Similarly, self-19 
complementary AAV vectors have been shown to stimulate TLR9 more efficiently than single-20 
stranded vectors in mice and may yield enhanced benefits with the TLR9-inhibitory approach. 21 
The described strategy could be further optimized for improved results by exploring the 22 
incorporation of more potent TLR9i sequences or more copies of TLR9i sequences, and testing 23 
different or multiple locations in the AAV vector genome. Finally, incorporation of TLR9i 24 
sequences may be broadly useful for reducing immunogenicity of both viral and non-viral DNA 25 
delivery, such as adenoviral vectors and lipid nanoparticles.  26 
 To date, many AAV clinical studies have relied on prophylactic or reactive 27 
corticosteroids to suppress immune responses such as intraocular inflammation and liver 28 
transaminase elevation. In addition, reducing or eliminating CpG content from parts of the AAV 29 
vector genome, such as the transgene coding region, to reduce TLR9 activation also has been 30 
explored. Future studies are needed to understand how our approach compares to corticosteroid 31 
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treatment and CpG depletion for different routes of administration and vectors, and whether 1 
combining these approaches is beneficial. 2 
 There are some limitations to our study and the TLR9-inhibitory approach. Our 3 
experimental models tested the effects of io1 and io2 for 4 weeks to 3 months, a time period 4 
assumed to give stable or near-stable expression. Longer term studies would provide more 5 
information on durability of expression and the observed enhanced expressions. Moreover, while 6 
specific antagonism of TLR9 in AAV gene therapy has several benefits which we report in this 7 
study, our approach may not translate to complete suppression of all immune responses 8 
clinically, depending particularly on dose, route of administration and type of transgene. For 9 
example, we observed no impact on the formation of Nabs against AAV capsid and reduced 10 
effects on preventing anti-capsid T cell responses in highly immunogenic settings. Furthermore, 11 
incorporation of TLR9i sequences suppressed the extent of ocular T cell infiltrate induced by 12 
intravitreal AAV in mice, but the response was not eliminated. This may reflect incomplete 13 
TLR9 blockade with io2, or a potential influence of other non-TLR9 factors that are operative 14 
within and specific to the ocular environment. Future studies should seek to characterize 15 
intravitreal AAV-mediated inflammation in Tlr9 and Myd88 knock-out mice. Additionally, the 16 
approach may not block anti-transgene immune responses, as TLR9 is not thought to be essential 17 
for such responses. Finally, future studies should focus upon immunomodulatory strategies that 18 
synergize with the TLR9-inhibitory approach to further mitigate immune responses.  19 
 The immunogenicity challenges of intravitreal administration of AAV are well-20 
recognized compared to subretinal administration (35). While the TLR9-inhibitory approach did 21 
not prevent clinical uveitis in NHPs at the higher dose of 5 x 1011 vg, our work marks a 22 
significant step in recognizing and addressing the inflammation. This may be surmounted in the 23 
future by identifying new factors mediating intraocular inflammation and combining 24 
immunomodulatory strategies like the TLR9-inhibitory approach. Limitations of the intravitreal 25 
NHP experiment include a single experiment of small and underpowered sample size per group 26 
to demonstrate a clinically significant effect, substantial intra-group variability in inflammation 27 
and expression, and a lack of understanding of inflammation at the tissue level via 28 
histopathology or cell immune phenotype characterization. Furthermore, the intravitreal NHP 29 
experiment utilized a secreted human transgene protein, and we did not attempt to measure if 30 
anti-drug antibodies (ADAs) formed in the NHPs. As there were less positive benefits of our 31 
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approach with intravitreal delivery in NHPs compared to multiple mouse models and the pig 1 
model, it would be prudent to test our approach with other routes of administration in NHPs. 2 
Finally, the observation that prophylactic systemic steroids also delayed, but did not prevent, 3 
clinical uveitis may have important implications for clinical protocols for intravitreal AAV 4 
therapies.  5 
Recent successes in AAV gene therapy in the clinic (4, 36) highlight the potential for in 6 
vivo gene therapy to treat multiple types of disorders. However, as the field moves beyond the 7 
most devastating diseases, there is a pressing need to address host immune responses (2-8). 8 
Furthermore, several ocular AAV gene therapy trials have reported intraocular inflammation at 9 
therapeutically relevant doses (see Figure S18 and S19 for analysis). In this study, we sought to 10 
develop AAV vectors that are intrinsically less immunogenic by exploiting the linkage of 11 
specific immunomodulatory non-coding sequences to much longer therapeutic nucleic acids to 12 
“cloak” the AAV genome from immune responses. We directly compared AAV vectors with or 13 
without TLR9i sequences in experiments encompassing different capsid serotypes, genome 14 
configurations, promoters and transgenes, target tissues, routes of administration and animal 15 
models, and showed marked reduction of immune responses without changing any other 16 
sequences in several models. This “coupled immunomodulation” strategy may offer a versatile, 17 
broadly applicable solution for different AAV therapies without impacting capsid or vector 18 
genome elements such as promoter choice, and may be a crucial part of the solution for highly 19 
immunogenic AAV therapies. Our approach may widen the therapeutic window of gene therapy, 20 
contribute to gene therapy applications, and guide the design of future nucleic acid-based 21 
therapeutics.  22 
  23 
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MATERIALS AND METHODS 1 
 2 
Study design 3 
The overall goal of this study was to determine if incorporating TLR9-inhibitory sequences 4 
in AAV vector genomes elicited reduced immune responses, and in certain models, 5 
increased transgene expression. The general approach was to select an experimental model 6 
with known immunogenicity in the literature, and directly compare an unmodified AAV 7 
vector to an engineered AAV vector under similar conditions in our laboratories. In most 8 
cases, vehicle injections served as a negative control to determine baseline immune 9 
responses.  10 
For the intravitreal mouse study, laterality of injected eyes was randomized, and 11 
investigators were masked to the vector type throughout intervention and analysis. 12 
 For the subretinal pig study, the retinal surgeon performing the injections was blinded to 13 
the test article, and similarly, clinical examinations and scoring of inflammation were 14 
performed blinded. For the intravitreal NHP study, the veterinary ophthalmologist was 15 
masked to the test article when performing injections and scoring of inflammation. All other 16 
studies and experiments were not performed blinded.  17 
All animal protocols were approved by respective institutions and committees. 18 
Cryopreserved peripheral blood mononuclear cells (PBMCs) from de-identified healthy 19 
donors were purchased from commercial providers with written informed consent from the 20 
donor and were used in accordance with Declaration of Helsinki principles. Sample size was 21 
chosen empirically based on results of previous studies. In general, three to six replicates for 22 
each condition was used per experiment, with precise numbers provided in the figure 23 
legends. All in vitro experiments were performed at least twice independently. Some data 24 
points were excluded from analyses due to: a sample with abnormal amplification curve 25 
during qPCR, an IFN-g ELISpot well with too many spots to count for the plate reader, and 26 
lack of immune responses for some PBMC donors. Data file S1 contains all raw data 27 
including excluded data points.  28 
 29 
Mice 30 
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7-9-week-old male C57BL/6J mice were purchased from the Jackson Laboratory. Tlr9-/- 1 
mice were a gift of D. Golenbock (UMass), who had originally received the mice from S. 2 
Akira (Osaka U.), and were bred at Harvard Medical School. Myd88-/- mice 3 
[B6.129P2(SJL)-Myd88tm1.1Defr/J] also were purchased from the Jackson Laboratory, then 4 
bred at Harvard Medical School. These mice were housed at Harvard Medical School under 5 
specific pathogen free conditions with food and water ad libitum. All mouse experimental 6 
protocols performed at Harvard (intravenous and intramuscular AAV experiments in this 7 
study) were approved by Harvard Medical School Institutional Animal Care and Use 8 
Committee. 9 
6-8-week-old C57BL/6J male mice were purchased from Charles River Laboratories, Oxford, 10 
UK and housed at the University of Bristol Animal Services Unit under specific pathogen free 11 
conditions with food and water ad libitum. All procedures (intravitreal AAV experiments in this 12 
study) were conducted in concordance with the United Kingdom Home Office licence (PPL 13 
30/3045) and were approved by the University of Bristol Animal Welfare and Ethical Review 14 
Group.  The study also complied with the Association for Research in Vision and 15 
Ophthalmology (ARVO) Statement for Use of Animals in Ophthalmic and Vision Research.  16 
 17 
AAV vectors 18 
Self-complementary (sc) or single-stranded (ss) AAV vectors were used in this study and all vector 19 
genomes were flanked by AAV2 ITRs. Self-complementary AAV vectors lack the terminal 20 
resolution sequence in one ITR and allow earlier and increased transgene expression compared to 21 
single-stranded vectors. Unless indicated as self-complementary, all vectors were single-stranded. 22 
scAAV.FIX was a kind gift from R. Herzog (Indiana University School of Medicine, formerly U. 23 
of Florida) and has been described previously (16). scAAV.FIX expressed human factor IX (FIX) 24 
under the control of a liver-specific transthyretin mouse promoter and included a bovine growth 25 
hormone polyA sequence. AAV.GFP (single-stranded) was originally obtained from the Harvard 26 
DF/HCC DNA Resource Core (clone ID: EvNO00061595) and contained a CMV 27 
enhancer/promoter, human b-globin intron, eGFP, and b-globin polyA sequence (37). 28 
AAV.GFP.WPRE (single-stranded) was a kind gift from L. Vandenberghe (Massachusetts Eye 29 
and Ear Infirmary, MEEI) and contains a CMV promoter and woodchuck hepatitis virus post-30 
transcriptional regulatory element (WPRE) for eGFP expression. To distinguish the two single-31 
Confidential - Manuscript 
19 
 
stranded GFP vectors, we have denoted the former as AAV.GFP and the latter as 1 
AAV.GFP.WPRE. The single-stranded AAV.FIX vector was constructed by swapping out the 2 
CMV promoter and GFP transgene in AAV.GFP.WPRE for CAG promoter and human FIX 3 
respectively. Finally, the single-stranded AAV2.aflibercept vector was synthesized by Genscript 4 
and contains the CAG promoter, codon-optimized aflibercept with the human growth hormone 5 
signal peptide, and the rabbit b-globin polyA sequence. 6 
To engineer scAAV.FIX, sequences were inserted into the unique KpnI site found immediately 5’ 7 
of the transthyretin promoter. 3 copies of ODN TTAGGG 8 
(TTTAGGGTTAGGGTTAGGGTTAGGG) were inserted, separated by AAAAA linkers (termed 9 
“io1” for inflammation-inhibiting oligonucleotide 1). A widely used ODN TTAGGG 10 
(manufactured by Invivogen, catalog code “tlrl-ttag”) harbored an additional T (in bold) compared 11 
to published studies and thus was included in the sequence. During the course of this study, 12 
Invivogen removed the additional T in their manufactured oligonucleotide (catalog code “tlrl-13 
ttag151”). No differences in TLR9-inhibitory activity were observed with or without the inclusion 14 
of the additional T. 15 
To engineer AAV.GFP, KpnI – [3 copies of ODN TTAGGG with linkers (positive sense)] – [3 16 
copies of INH18 with linkers (negative sense)] – NheI (termed “io2” for inflammation-inhibiting 17 
oligonucleotide 2) was inserted immediately 5’ of the XbaI site just upstream of the right ITR. 18 
Again, AAAAA was used as a linker between copies of ODN TTAGGG and INH18. Similarly, to 19 
engineer AAV.GFP.WPRE and AAV.FIX, KpnI-io2 was inserted immediately 5’ of the XhoI site 20 
just upstream of the right ITR. AAV2.aflibercept and AAV2.aflibercept.io2 were synthesized in 21 
parallel with the io2 sequence positioned immediately 3’ of the KpnI site just upstream of the right 22 
ITR. As single-stranded AAV vectors have an equal chance of packaging positive or negative 23 
strands of the viral genome, we added both sense and anti-sense TLR9-inhibitory sequences. This 24 
strategy ensured that all packaged AAV genomes will carry copies of TLR9-inhibitory sequences 25 
in the right orientation.  26 
AAV vectors were packaged into AAV2, AAV8 and AAVrh32.33 capsids and were purified by 27 
the viral vector core facility Gene Transfer Vector Core at MEEI/Harvard except for those noted 28 
otherwise below. Briefly, adenoviral helper plasmid, rep2-cap packaging plasmid, and transgene 29 
Confidential - Manuscript 
20 
 
plasmid were transfected at a ratio of 2:1:1 (260 µg of adenoviral helper plasmid, 130 µg of rep2-1 
cap packaging plasmid, 130 µg of transgene plasmid) into approximately 80% confluent HEK293 2 
cells with polyethylenimine in ten-layer HYPERFlasks (Corning, CLS10030). PEI Max 3 
(Polysciences)/DNA ratio was maintained at 1.375:1 (w/w).  The supernatant and cells were 4 
collected 72 h after transfection and cell lysates were formed by three sequential freeze-thaw 5 
cycles. The viral solution was incubated with 25 U/ml Benzonase (EMD Millipore) at 37°C for 1 6 
h, and NaCl was added to a final concentration of 650 mM, then the viral solution was kept at 4 7 
⁰C for overnight. Cell debris was removed by high speed centrifugation, then the supernatant was 8 
collected and run through Tangential Flow Filtration to concentrate the volume to around 10 mL 9 
and then run on an iodixanol gradient. Recovered AAV vectors were washed 3 times with final 10 
formulation buffer (FFB: 1 x PBS + 35 mM NaCl + 0.001% PF68) using Amicon 100K columns 11 
(EMD Millipore) and concentrated to ~600 – 1000 µl of FFB.  12 
The viral titers were determined by digital droplet PCR (ddPCR) using primers directed against 13 
the promoter or poly-adenylation signal regions of the transgene cassette. The purity of vector 14 
preps was evaluated by running 1 x 1010 vg (viral genome) on an SDS-PAGE gel. In addition, 15 
vector preps had < 1EU/ml of endotoxin using a limulus amebocyte lysate assay (ToxinSensor 16 
Chromogenic LAL Endotoxin Assay Kit, Genscript). No substantial differences in viral yield (viral 17 
titer x volume) were observed between unmodified vectors and corresponding engineered vectors 18 
for >20 purifications, suggesting that insertion of the described sequences did not hamper viral 19 
packaging.  20 
AAV2.GFP.WPRE and AAV2.GFP.WPRE.io2 were run on an iodixanol gradient as above and 21 
recovered vectors underwent an additional purification step using a heparin column and two 22 
washes of 25 ml of PBS plus 0.1 M NaCl as previously described (38). The eluate was then washed 23 
with FFB and concentrated as above. These vectors were originally produced for a different large 24 
animal study and were used on human PBMCs in vitro as they are highly purified. In addition, 25 
during the course of revising the manuscript, more vectors were made at Genethon for human 26 
PBMC testing. They were produced by triple transfection method as previously described (39). 27 
Briefly, HEK293 cells were transfected and harvested after 72h, followed by sonication and 28 
benzonase treatment. Vectors were purified by two successive ultracentrifugation rounds in cesium 29 
chloride density gradients. Vector titer was determined by quantitative real-time PCR (qPCR) and 30 
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confirmed by SDS-PAGE, followed by SYPRO Ruby protein gel stain (Lonza, Rockland, ME). 1 
IL-1b/IL-6 staining experiments were performed with Harvard-produced vectors (iodixanol + 2 
column purification) and IFN-b staining experiments were performed with Genethon-produced 3 
vectors (cesium chloride purification). 4 
AAVrh32.33.FIX and AAVrh32.33.FIX.io2 vectors (for intramuscular AAV mouse 5 
experiments), AAV2.GFP.WPRE and AAV2.GFP.WPRE.io2 vectors (for intravitreal AAV 6 
mouse experiments) and AAV2.aflibercept and AAV2.alifbercept.io2 vectors (for intravitreal 7 
NHP experiment) were produced by transient HEK293 cell transfection and cesium chloride 8 
sedimentation by the University of Massachusetts Medical School Viral Vector Core, as 9 
previously described (40). Vector preparations were titered by ddPCR, and purity was assessed 10 
by 4%–12% SDS-acrylamide gel electrophoresis and silver staining (Invitrogen) or Coomassie 11 
staining (Rockland Inc Cat# MB-023-1000). Aflibercept vectors and vehicle, as well as positive 12 
and negative control samples, were inoculated in growth media and incubated for 48 h (luria 13 
broth agar) or 2 weeks (soybean casein digest and fluid thiolglycollate medium liquid media), 14 
and sterility was assessed by observing microbial growth. Endotoxin testing showed < 1 EU/ml 15 
of endotoxin. 16 
The percentage of full and empty capsids for preparations of AAV8.GFP and AAV8.GFP.io2 17 
was determined by negative stain electron microscopy. Formvar/carbon-coated copper mesh 18 
grids (Electron Microscopy Sciences, Hatfield, PA) were glow discharged and loaded with 5 x 19 
1010 vg of AAV8.GFP or AAV8.GFP.oligo in PBS for 5 minutes. Grids were washed twice in 20 
dH2O and stained with 0.5% uranyl acetate. After drying, grids were imaged on an FEI Tecnai 21 
T12 transmission electron microscope (FEI, Hillsboro, OR) equipped with a Gatan UltraScan 22 
895 4k CCD (Gatan, Pleasanton, CA). 10 images for each sample were processed in ImageJ and 23 
particles counted based on the intensity of uranyl acetate staining. Empty capsids had a distinct 24 
dark staining in the center of the capsid. The percentage of full capsids was determined for each 25 
image and was reported as the average percentage and standard deviation across 10 images. 26 
Negative stain electron microscopy of AAV2.aflibercept and AAV2.aflibercept.io2 was 27 
performed at the University of Massachusetts Medical School Viral Vector Core using a 1% 28 
uranyl acetate stain. After removing excess stain and drying the grids, 6 images of each vector 29 
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were processed to determine the percentage of full capsids and was reported as the average 1 
percentage with standard deviation across the 6 images. 2 
 3 
Mouse liver studies in vivo 4 
Adult C57BL/6J or Tlr9-/- or Myd88-/- mice were injected intravenously with 100 µl PBS or 5 
AAV8 self-complementary viruses (1 x 1010 vg or 1 x 1011 vg per animal) by tail vein injection 6 
as previously described (16). For innate immune responses, the animals were sacrificed 2 h later 7 
and a portion of the right median lobe of the liver was saved in RNAlater solution (Thermo 8 
Scientific) and a portion of the left median lobe was fixed in 10% formalin overnight and 9 
transferred to 70% ethanol.  10 
For quantitative PCR (qPCR), total RNA was extracted from 10 – 30 mg of mechanically 11 
disrupted liver sample by using an RNA extraction kit (OMEGA Bio-Tek). Similar amounts of 12 
RNA were reverse transcribed into cDNA with a high-capacity RNA-to-cDNA kit (Thermo 13 
Scientific) and cDNA was assayed with quantitative PCR (qPCR) using TaqMan Fast Advanced 14 
Master Mix (Thermo Scientific) and commercially available pre-designed primers/probes with 15 
FAM reporter dye for the indicated target genes (IDT). Expression for each gene were calculated 16 
by normalizing against the housekeeping genes Actb or Gapdh using the ΔΔCT method and 17 
expressed as fold expression compared to saline-injected mice. The p values are calculated based 18 
on a two-tailed Mann-Whitney test comparing fold expression. All qPCR reactions were run on a 19 
realplex4 MasterCycler (Eppendorf).  20 
For histology, liver samples were processed at Beth Israel Deaconess Medical Center histology 21 
core facility. The immunohistochemistry staining was performed on paraffin embedded mouse 22 
liver tissue sections that were cut, deparaffinized and hydrated before use. Antigen retrieval was 23 
performed by boiling the slides for 10 minutes in 10mM sodium citrate in a pressure cooker. The 24 
samples were stained for F4/80+ macrophages (1:50, ab16911, Abcam) overnight at 4oC and 25 
incubated with goat anti-rabbit IgG conjugated with HRP polymer (ab214880, Abcam) for an 26 
hour at room temperature. The slides were developed using DAB (Diaminobenzidine) metal 27 
enhanced kit (Vector lab, Cat#: SK4105), counter stained with hematoxylin (Thermo Fisher) and 28 
processed through dehydration steps before mounted in Permount mounting media. The slides 29 
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were observed under the Zeiss Axio Zoom V16 microscope under a 1x/0.25 objective. Five 1 
random 25x brightfield images per sample slide were captured by AxioCam 506 digital camera 2 
using Zeiss Zen Pro imaging software. The macrophages were counted using the count tool 3 
feature in the Adobe Photoshop software and the data was calculated per millimeter square. 4 
For hFIX expression, plasma (EDTA) samples were obtained 14 d and 28 d after AAV 5 
administration and hFIX expression was quantified by analyzing diluted plasma samples using 6 
an ELISA kit specific for human factor IX (ab188393, Abcam). Plasma from PBS-injected mice 7 
gave signals similar to that of a blank control, demonstrating specificity of the kit for human 8 
factor IX. The kit had a sensitivity of at least 0.78 ng/ml.  9 
In vitro AAV neutralizing antibody (NAb) assays were performed on plasma samples 28 d after 10 
PBS or 1 x 1011 vg AAV8 administration as previously described (41) with the following 11 
modifications: plasma samples were heat-inactivated and diluted 1:40 in DMEM followed by 12 
five 3-fold serial dilutions. β-galactosidase activities in cell lysates were measured using the 13 
Galacto-StarTM One-Step β-galactosidase Reporter Gene Assay System (Thermo Fisher 14 
Scientific) on a Synergy HT microplate luminometer (BioTek). The transduction inhibition test 15 
samples at each dilution was normalized by comparing to naïve mouse serum (S-3509, Sigma-16 
Aldrich) at the same dilutions.  17 
 18 
Mouse muscle studies in vivo 19 
Adult C57BL/6J or Myd88-/- mice were injected intramuscularly (i.m.) with 50 µl PBS or 20 
AAVrh32.33 single-stranded viruses (1 x 1010 or 1 x 1011 vg per animal) encoding GFP or hFIX 21 
in the left quadriceps muscle. 21 d later, the animals were sacrificed and a portion of the 22 
quadriceps was fixed in 10% formalin overnight and transferred to 70% ethanol. For histology, 23 
muscle samples were processed at Dana-Farber/Harvard Cancer Center Specialized 24 
Histopathology Services and Beth Israel Deaconess Medical Center histology core facilities, 25 
embedded in paraffin, and stained for CD8 (1:500, D4W2Z, CST) and granzyme B (1:500, 26 
polyclonal, catalog # AF1865, R&D). Antibodies were tagged with AlexaFluor 488 Tyramide or 27 
AlexaFluor 647 Tyramide (B40957 and B40958, Thermo Fisher). All immunohistochemistry 28 
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was performed on the Leica Bond automated staining platform using the Leica Biosystems 1 
Refine Detection Kit with citrate antigen retrieval. Muscle sections also were stained for GFP 2 
(1:800, polyclonal, catalog # ab6556, Abcam) using the Leica Biosystems Refine Detection Kit 3 
(DAB chromogen) with EDTA antigen retrieval. For rh32.33.FIX injected mice, plasma samples 4 
were obtained 14 d, 28 d, 42 d and 60 d after 1 x 1011 vg AAV administration and hFIX 5 
expression was measured by ELISA as previously described. 6 
 7 
IFN-g T cell ELISpot assays 8 
Spleens were harvested from C57BL/6J or Myd88-/- mice injected i.m. with scAAV8.FIX or 9 
AAVrh32.33 single-stranded vectors 21 d post-injection. Spleens were passed through a 70 10 
µm cell strainer (Fisher Scientific), and dissociated cells were spun down. The cell pellet 11 
was treated with 1 ml of ACK lysing buffer (Life Technologies) to lyse red blood cells. To 12 
determine the number of cells secreting IFN- g in response to antigenic stimulation, we used 13 
an IFN-g ELISpot assay based on manufacturer’s instructions (R&D Systems). Briefly, 96-14 
well plates were pre-blocked with RPMI growth media for 2 h at room temperature and 15 
rinsed twice with PBS. 5 x 105 splenocytes were seeded per well in T cell medium (DMEM 16 
supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 10 mM HEPES 17 
buffer, 0.1 mM non-essential amino acids, 2mM sodium pyruvate and 10-6 M beta-18 
mercaptoethanol, with 2 µg/ml of a CD8+ h2-kb restricted dominant epitope of AAVrh32.33 19 
capsid (SSYELPYWM, purchased from Genemed Synthesis) or incubated with 20 
PMA/ionomycin as a non-specific positive control for 18 h, followed by staining. For 21 
scAAV8.FIX-treated animals, 2 µg/ml of an AAV8-derived immunodominant epitope 22 
NSLANPGIA (Genemed Synthesis) was used instead. ELISpot plates were evaluated in 23 
blinded fashion (ZellNet Consulting, Inc.) using an automated ELISpot reader system (KS 24 
ELISpot reader, Zeiss) with KS ELISpot software version 4.9.16. The plate evaluation 25 
process including the setup of optimal reading parameters followed the International 26 
guidelines on ELISpot plate evaluation (42). 27 
 28 
Mouse intravitreal AAV injection and clinical assessment  29 
Mice were anaesthetised using intraperitoneal injection of 90 µL/10 g body weight of a solution 30 
of Ketavet (Ketamine hydrochloride 100 mg/mL; Zoetis Ireland Ltd.) and Rompun (Xylazine 31 
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hydrochloride 20 mg/mL; Bayer PLC) mixed with sterile water in the ratio of 0.6:1:8.4 1 
respectively. Pupils were dilated with a single drop of 1% w/v Tropicamide (Chauvin 2 
Pharmaceuticals) prior to injection.  2µL volume of titer-matched AAV at 5 x 1012 vg/mL was 3 
delivered into the intravitreal space via the pars plana, using an operating microscope and a 33-4 
gauge needle on a microsyringe under direct visualisation (Hamilton Company). The 5 
contralateral eye of each animal received a control injection of PBS.  Immediately following 6 
injection, 1% Chloramphenicol ointment (Martindale Pharma, Wooburn Green, UK) was applied 7 
topically, and the animals were warmed on a heat-pad for recovery. Laterality of injected eyes 8 
was randomized, and investigators were masked to the vector type throughout intervention and 9 
analysis. 10 
On selected days post-injection (dpi), pupils were dilated, and mice anaesthetised using 11 
isofluorane 2% (v/v) by inhalation for clinical assessment. The Micron IV retinal imaging 12 
microscope (Phoenix Research Laboratories) was used to capture OCT scans and color and 13 
fluorescence fundal images.   14 
 15 
Isolation and flow cytometric assessment of mouse retinal immune cell infiltrate 16 
Each eye was dissected in 100 μl ice-cold PBS with aqueous, vitreous and retina extracted using 17 
a limbal incision, lens removal and transfer into a 1.5 mL microcentrifuge tube. The tissue was 18 
mechanically dissociated by rapping the tube across a 80-well standard rack ten times before 19 
transfer into a 96-well 60 μm cell strainer plate (Merck Millipore). This was centrifuged at 1200 20 
rpm for 5 minutes and the supernatant aspirated, and the remaining cell pellet resuspended in 21 
0.1% BSA FACS buffer and transferred into a 96-well V-bottom plate for immuno-staining. 22 
Cells were incubated with purified rat anti-mouse CD16/32 Fc block (1:50, 553142, 23 
[2.4G2], BD Biosciences (BD)) for 10 minutes at 4oC before incubation with fluorochrome-24 
conjugated monoclonal antibodies against mouse cell surface markers including, CD45 25 
[1:1500, 552848, [30-F11], BD), CD3 (1:40, 100355, [145-2C11], BioLegend), CD4 26 
(1:100, 553051, [RM4-5], BD), CD8 (1:200, 126622, [YTS156.7.7], BioLegend), at 4oC for 27 
20 minutes. Cells were washed and resuspended in 7-aminoactinomycin D (7AAD; Thermo 28 
Fisher) for dead cell exclusion. Cell suspensions were acquired using a fixed and stable flow 29 
rate for 2.5 minutes on a 4-laser Fortessa X20 flow cytometer (BD Cytometry Systems). 30 
Compensation was performed using OneComp eBeads (01-1111-41, ThermoFisher).  Eight 31 
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two-fold serial dilutions of a known concentration of AccuCheck Counting Beads (PCB100, 1 
ThermoFisher) were similarly acquired to construct a standard curve and calculate absolute 2 
cell numbers (43). Analysis was performed using FlowJo software (Treestar) (gating 3 
strategy as shown in fig. S9).  4 
 5 
Subretinal injection of AAV in domestic pigs  6 
All experimental protocols using pigs were performed at the University of Louisville, were 7 
approved by the University of Louisville Institutional Animal Care and Use Committee and 8 
adhered to the ARVO Statement for Use of Animals in Ophthalmic and Vision Research. 9 
Six 50-day-old wild-type domestic female pigs were purchased (Oak Hill Genetics). 10 
Surgery to inject AAV into the subretinal space was performed after a one-week 11 
acclimatization period at the University of Louisville AALAC-approved facility. Details 12 
have been published previously (44-46). Animals were sedated via intravenous 13 
administration of: Ketamine (10 mg/kg) and Dexmedetomidine (0.04 mg/kg) and treated 14 
with Atropine (0.25 mg/kg). An endotracheal tube was inserted and through it isoflurane 15 
was administered to achieve a surgical plane of anesthesia (1 – 3%). An IV line inserted in 16 
the ear vein delivered IV fluids (Lactated Ringers Solution with or without 5% dextrose; 10 17 
– 15 mL/kg/h) to maintain blood pressure and normal glycemia (60 – 140 mg/dL). Body 18 
temperature was monitored every 30 min with a rectal thermometer and maintained via a 19 
heated procedure table. Heart and respiration rates and oxygen saturation were recorded 20 
every 10 min throughout the procedures and anesthesia adjusted to maintain a normal range 21 
for these physiological parameters. 22 
After anesthesia and aseptic surgical preparation, we used a vitreoretinal surgical approach to 23 
gain access to the subretinal space (between the retina and the pigment epithelium at the back of 24 
the eye). A lateral canthotomy was performed to increase exposure in the surgical field. After 25 
insertion of an eyelid speculum, two 25 g trocars were placed at 1.5 mm posterior to the limbus; 26 
one in superior-nasal and the other in inferior-nasal quadrant. An anterior chamber fluid 27 
paracentesis was performed to make space for the injected volume. A light pipe was inserted into 28 
one trochar to help visualize the retina. A 41-gauge subretinal cannula needle was placed through 29 
the other trochar and used to make a local retinal detachment (bleb) in the dorsal retina, which 30 
included injection of inoculum (~75 µl). The inoculum contained either AAV8.GFP.io2 or 31 
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AAV8.GFP in FFB, or FFB alone (vehicle). We injected either AAV8.GFP.io2 or AAV8.GFP 1 
into OD or OS of two pigs in each of three surgery sessions (total of 10 AAV-treated eyes, 1 2 
FFB-injected eye and 1 uninjected control eye). After the injection, the light pipe, needle and the 3 
trochars were removed and the entry sites left to self-seal. At the end of surgery, the lateral 4 
canthotomy was sutured closed with 4-0 Nylon and antibiotic and steroid ointment was topically 5 
administered.  6 
From 2 weeks post-injection (wpi) to 6 wpi, a complete clinical examination assessed the health 7 
of the retina at weekly intervals in anesthetized pigs. This included a slit lamp examination to 8 
inspect the anterior segment of the eye and to characterize damage to the cornea/lens, indirect 9 
ophthalmoscopy to inspect the health of the fundus and fundus photography to document the 10 
state of the retina, its optic nerve, the blood vessel pattern, and any damage that resulted from 11 
surgical procedures or viral expression. In addition, each eye was scored for inflammation of the 12 
eye/retina using the Standardization of Uveitis Nomenclature (SUN) classification (47). The 13 
retinal surgeon performing the injections was blinded to the test article, and similarly, clinical 14 
examinations and scoring of inflammation were performed blinded.  15 
Prior to surgery and at 2 and 6 wpi, OCT (Bioptigen/Leica Biosciences) was performed to 16 
image the retinal layers of anesthesized pigs in vivo. Pupils were dilated and 17 
accommodation relaxed with topical applications of 2.5% phenylephrine hydrochloride and 18 
1% Tropicamide. Lid specula held the eyelids open and corneas were wet throughout the 19 
imaging with artificial tears (Tears Again, OcuSoft, Inc). Using OCT b-scans we identified 20 
the retinotomy site and characterized the lamination pattern of the hypo- and hyper-21 
reflective bands as a function of distance from the retinotomy site in both the axial and 22 
lateral dimensions. We defined two types of damage: severe and non-severe. Severe damage 23 
were areas where the hyper-reflective bands representing the RPE and photoreceptor 24 
inner/outer segments were disrupted. Non-severe disruption were areas where at least one of 25 
these hyper-reflective bands was present, but one or both were thinner and thus less defined 26 
than in areas without damage. The shape, location and size of these two types of damage 27 
were measured using software provided with the OCT system. Specifically, calipers were 28 
placed over severe and flanking non-severe damage in b-scans across the fundus and their 29 
areas were computed and summed over the entire extent of damage. These areas were then 30 
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superimposed on the fundus image and the areas of damage compared to the areas of GFP 1 
expression (see below).    2 
At 6 wpi (terminus), pigs were anesthetized and euthanized with a solution of Beuthanasia 3 
(390 mg pentobarbital sodium, 50 mg phenytoin sodium/ml; 1 mL/5 kg), and their eyes 4 
were enucleated. The cornea and lens were removed and the eyecup was dissected and fixed 5 
in 4% paraformaldehyde in PBS for 1 h at room temperature and then washed in PBS. 6 
Wholemount retinas were examined using a low power fluorescent microscope (Olympus 7 
MVX10) and the region of GFP+ expression was located and images acquired and plotted 8 
on the fundus images relative to the blood vessels and optic nerve head. The retina was 9 
dissected so that the piece used for histology included all of the GFP+ region, as well as 10 
GFP- flanking regions.  11 
The pig retinal tissue was cryoprotected in graded sucrose solutions up to 30% sucrose in 12 
PBS, then embedded in a 1:1 mixture of 30% sucrose and optimal cutting temperature 13 
(OCT) compound (Tissue-Tek) followed by cryosectioning on a Leica CM3050S (Leica 14 
Microsystems). Transverse sections of retinal tissue were cut at 20 µm. For 15 
immunohistochemistry, tissue sections were first blocked with 5% donkey serum (if the 16 
secondary antibody was donkey-origin) or 5% goat serum (if the secondary antibody was 17 
goat-origin) in PBS with 0.1% Triton X-100 for 1 h at room temperature. Sections were then 18 
stained overnight at 4 °C in blocking solution with primary antibodies against red-green 19 
opsin (1:600, AB5405, EMD Millipore), blue opsin (1:200, AB5407, EMD Millipore), 20 
human cone arrestin (48) (1:10000), Iba1 (1:200, ab5076, Abcam) or CD8 (1:200, 21 
MCA1223GA, Bio-Rad), followed by staining for 2 h at room temperature with goat anti-22 
rabbit, donkey anti-mouse, or donkey anti-goat AlexaFluor 594-labeled secondary 23 
antibodies (111-585-144, 715-585-150 and 705-586-147, all from Jackson 24 
ImmunoResearch) used at 1:1000 in PBS. Sections were then stained with 4’,6-diamidino-2-25 
phenylindole (DAPI) for 5 min and mounted using Fluoromount-G (Southern Biotech). The 26 
slides were examined using a LSM710 laser scanning confocal microscope (Zeiss) with a 27 
40x oil-immersion objective, and image processing was performed using ZEN software and 28 
ImageJ. For sections from AAV-injected eyes, care was taken to acquire representative 29 
images of GFP+ regions from the dorsal retina near, but not directly at, the retinotomy scar 30 
(where there is damage to photoreceptors from the injection). Images from the vehicle 31 
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control eye were likewise acquired from the dorsal retina near the area of bleb formation. 1 
Similar laser settings were used when acquiring images of the two eyes of each animal. 2 
To quantify the morphology of infected photoreceptors, we measured the inner segment plus 3 
outer segment (IS+OS) length of GFP+ cones, defined as the distance from the apex of the cone 4 
outer segment to the proximal edge of the nucleus. For each eye, the mean IS+OS length was 5 
calculated from 30 GFP+ cones over at least three different 20 µm sections. The number of 6 
Iba1+ cell bodies in the retina, Iba1+ processes extending into the ONL, and CD8+ cells 7 
infiltrating the retina also were quantified as described in fig. S13. 8 
 9 
Intravitreal injection of AAV in NHPs  10 
Experimental protocols using cynomolgus macaques (Macaca fascicularis) were performed 11 
at Charles River Laboratories and were approved by the Charles River Laboratories 12 
Institutional Animal Care and Use Committee. Thirty-three NHPs (2.5-3.5 years of age) 13 
with Nab titers in serum below 1:5 were used in the study. For AAV groups (five animals 14 
per group), two males and three females were dosed. For vehicle group (three animals), one 15 
male and two females were dosed. Animals were assigned randomly by weight to each 16 
group to achieve similar group mean body weights. 17 
The vehicle and test articles were administered by a board-certified veterinary 18 
ophthalmologist once on Day 1 via bilateral intravitreal injection (1 x 1011 vg or 5 x 1011 vg 19 
at a dose volume of 80 µl/eye). The animal was sedated/anesthetized to effect and placed in 20 
dorsal recumbency. Topical proparacaine was applied to the eyes, the conjunctival fornices 21 
were flushed with a 1:50 dilution of betadine solution/saline, and the eyelid margins were 22 
swabbed with undiluted 5% betadine solution. The eyes were draped, wire eyelid speculums 23 
were placed, and a caliper was used to mark a spot 3.0 mm posterior to the limbus on the 24 
inferotemporal bulbar conjunctiva. The conjunctiva, at the marked spot, was swabbed with 25 
undiluted 5% betadine solution. A 31-gauge needle was gently inserted tangentially through 26 
the limbus and into the anterior chamber to collect 40 µl of aqueous humor. Conjunctival 27 
forceps were used to fixate the globe position while a 31-gauge needle, affixed to the 28 
injection syringe, was inserted at the marked spot, through the sclera, and advanced into the 29 
vitreous humor. The injection needle was positioned to face the posterior axis of the globe 30 
and 80 µl of vehicle or test article was delivered into the vitreous by slowly depressing the 31 
Confidential - Manuscript 
30 
 
plunger. The needle was held in place for 30 seconds to lessen reflux of the injected 1 
material. Subsequently, the needle was removed, and the episcleral tissues approximated to 2 
the site of insertion were grasped with the conjunctival forceps to further lessen reflux of the 3 
injected material. The contralateral eye was prepared, and an identical injection procedure 4 
was performed. All animals received bilateral injections of the same test article, except for 5 
Animal 5 of Group 7, which only received 5 x 1011 vg AAV2.aflibercept.io2 injection in the 6 
right eye due to insufficient dosing solution (left eye was left uninjected). Some animals 7 
received prophylactic systemic immunosuppression in the form of an intramuscular 8 
injection of methylprednisolone (DepoMedrol 40 mg/animal) on Days -1 and 6. 9 
Ophthalmic examinations were performed on Day 3 and weekly from Week 1 to Week 12 10 
(termination) via slit-lamp biomicroscopy and indirect ophthalmoscopy. Uveitis was scored 11 
based on the SUN criteria system, assessing aqueous cells, aqueous flare, vitreous cells and 12 
vitreous haze. When AC or VC score was 3 or higher in an animal, the animal was treated 13 
with an intramuscular injection of methylprednisolone (40 mg/animal; up to 80 mg/animal if 14 
inflammation is severe). The injection was given weekly until AC = 0 and VC £ 1. 15 
At termination, ocular tissues, including vitreous humor, from one eye of each animal were 16 
collected and frozen, while the other eye was fixed for potential future histological analysis. 17 
 18 
ELISA for aflibercept 19 
in vitro expression in HeLa cells 20 
HeLa cells (3 x 104 cells/well in a 96-well plate) were transduced with AAV2.aflibercept or 21 
AAV2.aflibercept.io2 at 1 x 103 vg/cell, 1 x 104 vg/cell or 1 x 105 vg/cell in triplicate. 22 
Supernatants were harvested 48h post-transduction and analyzed for aflibercept expression 23 
(each sample run in duplicate). Briefly, high-binding 96-well ELISA plates (Corning 96 24 
well EIA/RIA plates, Cat# 3590) were coated overnight at 4°C with purified recombinant 25 
human VEGF165 (Shenandoah Biotechnology, Cat# 100-44) diluted in DPBS. The next 26 
day, excess VEGF165 was removed and wells were washed 4 times with 1x PBS followed 27 
by blocking for 1 h at 37°C with 5% BSA in PBS. Blocking solution was removed and 28 
HeLa cell supernatants and standards containing aflibercept were added to the wells and 29 
incubated for 1 h at 37°C. Following incubation, wells were washed 4 times with 1x PBS. 30 
Bound aflibercept was detected using a HRP-conjugated goat anti-human IgG, Fc-specific 31 
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antibody (Thermo Fisher, Cat# A18829) and ultra TMB substrate (Thermo Fisher, Cat# 1 
34028). A standard curve was prepared for each run using purified aflibercept (BOC 2 
Sciences, CAS 862111-32-8) of known concentration diluted in DMEM + 10% FBS. 3 
 4 
in vivo expression in NHP vitreous humor 5 
NHP vitreous humor was analyzed as above with the following changes. After blocking 6 
solution was removed, NHP samples and standards containing aflibercept were added to the 7 
wells and incubated for 1 hour at 37°C. Following incubation, wells were washed 4 times 8 
with 1x PBS. Bound aflibercept was detected using a HRP-conjugated goat anti-human IgG, 9 
Fcγ fragment-specific antibody (Jackson ImmunoResearch, Cat# 109-035-170) diluted in 10 
3% BSA in PBS and ultra TMB substrate. A standard curve was prepared for each run on 11 
each plate using purified aflibercept (BOC Sciences, CAS 862111-32-8) of known 12 
concentration diluted in cynomolgus macaque vitreous humor (BioIVT). NHP study 13 
samples were tested in 4 separate runs containing 3 dilutions/sample/run in technical 14 
duplicates. 15 
 16 
Statistical analysis 17 
Indicated statistical testing was performed as appropriate. Unpaired two-tailed Student’s t-tests 18 
were used to compare differences between two unpaired experimental groups in oligonucleotide 19 
testing in HEK293-TLR9 reporter cells in vitro. A two-tailed Mann-Whitney test or two-way 20 
ANOVA with Sidak’s post-hoc test or two-tailed Student’s t-test was used for most in vivo 21 
studies, as indicated.  A two-tailed Wilcoxon matched pairs signed ranked test was used for 22 
human PBMC IL-1b/IL-6 experiments and a two-tailed Student’s t-test for IFN-b experiments. 23 
A two-tailed Fisher’s Exact Test with stepdown Sidak adjustment for number of animals that 24 
reached clinical uveitis, a two-tailed generalized linear model for average time to reach clinical 25 
uveitis, and a univariate linear regression model with aflibercept expression as the outcome were 26 
used for analysis of the intravitreal NHP study. A P value of <0.05 was considered statistically 27 
significant. No pre-specified effect size was assumed and in general three to six replicates, 28 
animals, or donors for each condition was used per experiment.  29 
 30 
  31 
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Figure legends 1 
 2 
 3 
Figure 1. Innate immune response and human factor IX expression in mice following 4 
intravenous AAV8 administration. 5 
(A) Schematic diagram of vector organization of scAAV.FIX and scAAV.FIX.io1. The io1 6 
sequence is not expected to be transcribed or translated due to its placement in an untranslated 7 
region upstream of the promoter. (B) Innate immune response in liver assayed by qPCR 2 h after 8 
1 x 1011 vg AAV8 administration in C57BL/6 mice. n = 6 - 7 animals per condition. (C) Innate 9 
immune response in liver assayed by qPCR 2 h after 1 x 1010 vg AAV8 administration in 10 
C57BL/6 mice. n = 4 - 5 animals per condition. (D) Innate immune response in liver assayed by 11 
qPCR 2 h after 1 x 1011 vg AAV8 administration in Tlr9-/- mice. n = 4 animals per condition. (E) 12 
Innate immune response in liver assayed by qPCR 2 h after 1 x 1011 vg AAV8 administration in 13 
Myd88-/- mice. n = 4 animals per condition. PBS injection was set to 1-fold expression for each 14 
gene. Data shown are mean ± s.e.m. per condition. * p<0.05 by two-tailed Mann-Whitney test 15 
and compared against PBS condition. ns, not significant, p>0.05. (F) F4/80+ macrophage 16 
infiltration in C57BL/6 mouse liver 2 h after 1 x 1011 vg AAV8 administration. Data shown are 17 
mean of n = 6 - 7 animals per condition. * p<0.005 by two-tailed Mann-Whitney test. Scale bar, 18 
100 µm. (G) Human factor IX in plasma of C57BL/6 mice at indicated time points after 1 x 1011 19 
vg AAV8 administration. n = 7 - 8 animals per condition. (H) Human factor IX in plasma of 20 
C57BL/6 mice at indicated time points after 1 x 1010 vg AAV8 administration. n = 4 animals per 21 
condition. (I) Human factor IX in plasma of Myd88-/- mice at indicated time points after 1 x 1011 22 
vg AAV8 administration. n = 3 - 4 animals per condition. Data shown are mean ± s.d. per 23 
condition. ** p<0.005 by two-tailed Mann-Whitney test. ITR, inverted terminal repeat; TTR, 24 
transthyretin promoter; hFIX, human factor IX; bGH, bovine growth hormone poly(A) signal; 25 
TRS, terminal resolution site.  26 
 27 
 28 
Figure 2. Immune responses to single-stranded vectors in mouse skeletal muscle in vivo and 29 
human PBMCs in vitro.  30 
(A) CD8+ T cell responses to rh32.33 capsid 21 d after intramuscular injections. Representative 31 
images of the ELISpot well are shown. Dotted line (50 SFU/106 splenocytes) indicates cutoff for 32 
a positive T cell response. (B) Number of CD8+ T cells in the muscle sections (four fields per 33 
sample) of C57BL/6 mice for PBS and 1 x 1010 vg rh32.33 vectors. (C) Number of CD8+ 34 
Granzyme B+ T cells in the muscle sections (four fields per sample) of C57BL/6 mice for PBS 35 
and 1 x 1010 vg rh32.33 vectors. (D) Representative immunohistochemical images of CD8 and 36 
Granzyme B staining in the muscle sections of C57BL/6 mice for PBS and 1 x 1010 vg rh32.33 37 
vectors. White arrows indicate double positive cells. Scale bar, 10 µm. (E) Representative 38 
images of GFP expression (brown) by immunohistochemistry staining in muscle sections of 39 
C57BL/6 mice. Scale bar, 50 µm. (F) Human FIX in plasma of C57BL/6 mice at indicated time 40 
points following 1 x 1011 vg rh32.33 vector administration. Data shown are mean ± s.d. of n = 4 41 
animals per condition. (G) Intracellular cytokine staining of IL-1b in specific DC populations 24 42 
h after infection of primary human PBMCs from different donors (n = 13). (H) Intracellular 43 
cytokine staining of IFN-b 24 h after infection of primary human PBMCs from different donors 44 
(n = 7). Some donor PBMCs did not respond to AAV or LPS stimulation (no innate immune 45 
response induced over PBS-treated samples) and are not shown. Data shown are mean, with each 46 
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symbol representing an animal or a donor. n = 4 - 13 animals or donors per condition as 1 
indicated. *p<0.05 and **p<0.005 by two-tailed Mann-Whitney test for (A-D), two-way 2 
ANOVA with Sidak’s post-hoc test for (F), two-tailed Wilcoxon matched-pairs signed ranked 3 
test for (G), and two-tailed Student’s t-test for (H). ns, not significant, p>0.05. SFU, spot 4 
forming units.  5 
 6 
 7 
Figure 3. Engineered vector reduces retinal infiltration and achieves greater GFP transgene 8 
expression following intravitreal injection in mice. 9 
(A) Representative fundal and circular OCT scans of the retina 10 days after intravitreal injection 10 
with 2µl of titer-matched (5 x 1012 vg/mL) AAV2.GFP.WPRE, AAV2.GFP.WPRE.io2 or PBS 11 
control. Scale bars, 100 µm. Image annotations: optic disc (*), vasculitis (solid white arrow), 12 
vitreous cavity (VC), retinal vessels (open white arrow), photoreceptor layer (PR). By OCT, 13 
infiltrating cells entrapped within the optically empty vitreous gel above the retinal tissue are 14 
visualized as white dots. (B) At day 11 post-injection, eyes were dissected and processed by flow 15 
cytometry to identify and enumerate the absolute number of CD45+CD3+ and CD45+CD3+CD8+ 16 
T cell populations (n = 5-6 mice/group). Data shown are mean ± s.d., with each symbol 17 
representing a single eye. *p<0.05 and **p<0.005 by two-tailed Mann-Whitney test. (C) 18 
Standardized fluorescent in vivo retinal images captured on day 10 from AAV2.GFP.WPRE or 19 
AAV2.GFP.WPRE.io2 groups (n = 6 mice/group). (D) Flow cytometry of single retinas confirms 20 
higher numbers of GFP+ retinal cells and increased GFP geometric mean fluorescence intensity 21 
(gMFI) per individual cell. Dotted line indicates background (gMFI from normal retinal cell 22 
autofluorescence in PBS-injected eyes). Data shown are mean ± s.d., with each symbol 23 
representing a single eye. n = 6 eyes per group as indicated. *p<0.05 and **p<0.005 by two-tailed 24 
Mann-Whitney test. 25 
 26 
 27 
Figure 4. Engineered vector evades photoreceptor pathology and microglia and CD8+ T 28 
cell infiltration in subretinal-injected pig eyes. 29 
Immunohistochemical images of the ONL of pig retinas 6 weeks after subretinal injections. Each 30 
animal is indicated by an identification number and paired images are from the two treated eyes 31 
of each animal. (A) Outer segments of cone photoreceptors were visualized by anti-red-green 32 
(M) opsin staining. Scale bars, 10 µm. (B) Microglia proliferation and activation in the retina 33 
indicated by anti-Iba1 staining. Scale bars, 50 µm. (C) Cytotoxic T cell infiltration into the retina 34 
indicated by anti-CD8 staining. Scale bars, 50 µm. ONL, outer nuclear layer; Iba1, ionized 35 
calcium-binding adaptor protein 1. 36 
 37 
 38 
Figure 5. Engineered vector may delay, but does not prevent, intraocular inflammation 39 
following intravitreal AAV2 administration in NHPs. 40 
(A) Summary of NHP study design and key intraocular inflammation results. The indicated 41 
number of NHPs received bilateral intravitreal injections of AAV2.aflibercept or 42 
AAV2.aflibercept.io2 at 1 x 1011 vg or 5 x 1011 vg on Day 1, and intraocular inflammation was 43 
scored based on the SUN criteria system during the 12-week study. Group 6 and 7 animals 44 
received intramuscular injection of prophylactic systemic steroids on Days -1 and 6. Clinical 45 
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uveitis was defined as AC or VC score of 3 or higher. A two-tailed Fisher’s Exact Test with 1 
stepdown Sidak adjustment was used to analyze number of animals that reached clinical uveitis 2 
while a two-tailed generalized linear model was used to analyze average time to reach clinical 3 
uveitis. No statistically significant differences were detected between groups. (B)  Aflibercept 4 
concentrations (µg/mL) in NHP vitreous humors. Aflibercept concentrations were measured in 5 
NHP vitreous humor samples collected 12 weeks post-injection. For AAV-treated animals, 6 
animals 1 and 2 were male and animals 3 to 5 were female. For vehicle-treated animals, animal 1 7 
was male and animals 2 and 3 were female. A univariate linear regression model with aflibercept 8 
expression as the outcome was used to compare vitreous aflibercept concentrations in vector-9 
injected groups. No statistically significant differences were detected between groups. 10 
